Gensight Biologics SA Cash Flow-to-Debt Ratio
Gensight Biologics SA cash flow-to-debt ratio. Gensight Biologics SA (SIGHT) has a Cash Flow-to-Debt Ratio of -0.20x as of December 2025, meaning its operating cash flow of €-6.49 Million could theoretically repay 0% of its total liabilities (€33.20 Million) in one year. See SIGHT financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Gensight Biologics SA (2013–2025)
Cash flow-to-debt ratio of Gensight Biologics SA from 2013 to 2025. Historical debt coverage capacity for Gensight Biologics SA across 13 annual periods. Also explore SIGHT year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Gensight Biologics SA Cash Flow-to-Debt Ratio by Year (2013–2025)
Gensight Biologics SA cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Gensight Biologics SA. For the full cash flow conversion analysis, see Gensight Biologics SA cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.28x | €-9.38 Million | €33.20 Million | ▲ +17.7% |
| 2024 | -0.34x | €-12.94 Million | €37.68 Million | ▲ +44.5% |
| 2023 | -0.62x | €-24.66 Million | €39.83 Million | ▲ +24.4% |
| 2022 | -0.82x | €-33.75 Million | €41.22 Million | ▼ -94.3% |
| 2021 | -0.42x | €-17.14 Million | €40.66 Million | ▼ 0.0% |
| 2020 | -0.42x | €-15.04 Million | €35.69 Million | ▲ +68.9% |
| 2019 | -1.36x | €-28.11 Million | €20.74 Million | ▲ +37.4% |
| 2018 | -2.17x | €-28.38 Million | €13.11 Million | ▲ +16.8% |
| 2017 | -2.60x | €-18.78 Million | €7.22 Million | ▲ +21.9% |
| 2016 | -3.33x | €-19.64 Million | €5.89 Million | ▼ -92.6% |
| 2015 | -1.73x | €-12.09 Million | €6.98 Million | ▼ -33.0% |
| 2014 | -1.30x | €-5.52 Million | €4.24 Million | ▼ -27.2% |
| 2013 | -1.02x | €-1.95 Million | €1.91 Million | — |